Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study.

IF 4.8 2区 医学 Q1 ONCOLOGY
Oncologist Pub Date : 2024-11-16 DOI:10.1093/oncolo/oyae300
Pilar García-Alfonso, Paula Jimenez-Fonseca, Javier Soto-Alsar, Iosune Baraibar, Cristina Santos, Adelaida La Casta, Ismael Ghanem, Gema Pulido Cortijo, Axel Mariño Méndez, Roberto Pazo-Cid, Ruth Vera, Marcos Melián, Julia Alcaide, Begoña Graña, David Páez, Inmaculada Gallego, Miriam Lobo, Miguel Borregón, Ana Fernández Montes, Eva Martínez de Castro, Alberto Carmona-Bayonas, Enrique Aranda
{"title":"Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study.","authors":"Pilar García-Alfonso, Paula Jimenez-Fonseca, Javier Soto-Alsar, Iosune Baraibar, Cristina Santos, Adelaida La Casta, Ismael Ghanem, Gema Pulido Cortijo, Axel Mariño Méndez, Roberto Pazo-Cid, Ruth Vera, Marcos Melián, Julia Alcaide, Begoña Graña, David Páez, Inmaculada Gallego, Miriam Lobo, Miguel Borregón, Ana Fernández Montes, Eva Martínez de Castro, Alberto Carmona-Bayonas, Enrique Aranda","doi":"10.1093/oncolo/oyae300","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated significant paradigm shifts in gastrointestinal oncology patient management. This study captures the \"Zeitgeist\" of this period by analyzing adaptive strategies, treatment modifications, and survival outcomes, leveraging a 3-year follow-up perspective to extract insights from this unprecedented experience.</p><p><strong>Methods: </strong>We conducted a multicenter, retrospective cohort study utilizing the RETUD-TTD registry, encompassing 703 patients across 19 Spanish centers in April 2020. We evaluated alterations in clinical practice, therapeutic approaches, coronavirus disease 2019 (COVID-19)-related impacts, and patient survival. A Bayesian hierarchical model was employed to identify potential regional-specific frailties.</p><p><strong>Results: </strong>The peak of the pandemic in April 2020 catalyzed substantial shifts in oncological care delivery. Outpatient consultations decreased by 13%, with a notable selection bias toward cases with more favorable prognostic indicators. Multidisciplinary tumor board discussions were significantly curtailed (eg, mean monthly colorectal cancer cases discussed was reduced from 40 to 23), compromising qualitative care measures. This occurred concurrently with an average of over 3 oncologists per center on medical leave. Contrary to initial concerns, the healthcare system demonstrated remarkable resilience. The majority of patients received standard-of-care therapies with regulatory approval, albeit with regimen modifications in 15% of cases. These adaptations included extended dosing intervals, dose intensity modulations, and transitions to oral formulations while maintaining unexpectedly stable long-term survival outcomes. The Bayesian frailty model detected minimal unmeasured prognostic factors related to geographic location, and the type of pandemic-induced adaptation did not significantly impact survival. The model revealed that coronavirus disease 2019's impact was less pronounced than other core prognostic variables.</p><p><strong>Conclusions: </strong>The decentralized Spanish healthcare system exhibited substantial robustness in managing pre-pandemic diagnosed gastrointestinal malignancies, despite asymmetrical, and occasionally severe organizational disruptions. The insights gleaned from this experience could inform future crisis preparedness strategies and optimize care provision during subsequent public health emergencies.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyae300","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated significant paradigm shifts in gastrointestinal oncology patient management. This study captures the "Zeitgeist" of this period by analyzing adaptive strategies, treatment modifications, and survival outcomes, leveraging a 3-year follow-up perspective to extract insights from this unprecedented experience.

Methods: We conducted a multicenter, retrospective cohort study utilizing the RETUD-TTD registry, encompassing 703 patients across 19 Spanish centers in April 2020. We evaluated alterations in clinical practice, therapeutic approaches, coronavirus disease 2019 (COVID-19)-related impacts, and patient survival. A Bayesian hierarchical model was employed to identify potential regional-specific frailties.

Results: The peak of the pandemic in April 2020 catalyzed substantial shifts in oncological care delivery. Outpatient consultations decreased by 13%, with a notable selection bias toward cases with more favorable prognostic indicators. Multidisciplinary tumor board discussions were significantly curtailed (eg, mean monthly colorectal cancer cases discussed was reduced from 40 to 23), compromising qualitative care measures. This occurred concurrently with an average of over 3 oncologists per center on medical leave. Contrary to initial concerns, the healthcare system demonstrated remarkable resilience. The majority of patients received standard-of-care therapies with regulatory approval, albeit with regimen modifications in 15% of cases. These adaptations included extended dosing intervals, dose intensity modulations, and transitions to oral formulations while maintaining unexpectedly stable long-term survival outcomes. The Bayesian frailty model detected minimal unmeasured prognostic factors related to geographic location, and the type of pandemic-induced adaptation did not significantly impact survival. The model revealed that coronavirus disease 2019's impact was less pronounced than other core prognostic variables.

Conclusions: The decentralized Spanish healthcare system exhibited substantial robustness in managing pre-pandemic diagnosed gastrointestinal malignancies, despite asymmetrical, and occasionally severe organizational disruptions. The insights gleaned from this experience could inform future crisis preparedness strategies and optimize care provision during subsequent public health emergencies.

西班牙 COVID-19 大流行期间接受治疗的胃肠癌患者的三年生存随访:PANDORA-TTD20 研究数据。
导言:2020 年西班牙首次出现 SARS-CoV-2 大流行,促使胃肠道肿瘤患者管理模式发生重大转变。本研究通过分析适应策略、治疗调整和生存结果,捕捉到了这一时期的 "时代精神",并利用 3 年的随访视角,从这一前所未有的经历中汲取启示:2020年4月,我们利用RETUD-TTD登记处开展了一项多中心回顾性队列研究,涵盖了西班牙19个中心的703名患者。我们评估了临床实践的变化、治疗方法、冠状病毒病 2019 (COVID-19) 相关影响以及患者生存率。我们采用了贝叶斯分层模型来识别潜在的地区特异性弱点:结果:2020 年 4 月大流行的高峰期催化了肿瘤医疗服务的重大转变。门诊量减少了 13%,明显偏向于选择预后指标较好的病例。多学科肿瘤委员会讨论大幅减少(例如,平均每月讨论的结直肠癌病例从 40 例减少到 23 例),影响了定性护理措施。与此同时,每个中心平均有超过 3 名肿瘤学家休病假。与最初的担忧相反,医疗系统表现出了非凡的应变能力。大多数患者接受了监管部门批准的标准疗法,尽管有 15% 的病例对治疗方案进行了调整。这些调整包括延长给药间隔、调整剂量强度和过渡到口服制剂,同时保持了出乎意料的稳定的长期生存结果。贝叶斯虚弱模型检测到的与地理位置有关的未测量预后因素极少,大流行引起的适应类型对生存率没有显著影响。模型显示,2019 年冠状病毒疾病的影响不如其他核心预后变量明显:分散的西班牙医疗保健系统在管理大流行前确诊的胃肠道恶性肿瘤方面表现出了很强的稳健性,尽管出现了不对称和偶尔严重的组织中断。从这一经验中获得的启示可为未来的危机准备战略提供参考,并优化后续公共卫生突发事件中的医疗服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncologist
Oncologist 医学-肿瘤学
CiteScore
10.40
自引率
3.40%
发文量
309
审稿时长
3-8 weeks
期刊介绍: The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信